Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$5.01 - $9.46 $23,046 - $43,516
4,600 Added 35.66%
17,500 $157,000
Q1 2024

May 07, 2024

SELL
$6.87 - $9.31 $50,838 - $68,894
-7,400 Reduced 36.45%
12,900 $105,000
Q4 2023

Feb 14, 2024

SELL
$6.75 - $16.18 $2.72 Million - $6.53 Million
-403,300 Reduced 95.21%
20,300 $171,000
Q3 2023

Nov 14, 2023

BUY
$15.96 - $22.18 $6.41 Million - $8.91 Million
401,900 Added 1852.07%
423,600 $7.25 Million
Q2 2023

Aug 11, 2023

BUY
$15.65 - $24.1 $339,605 - $522,970
21,700 New
21,700 $503,000
Q4 2022

Feb 14, 2023

BUY
$17.09 - $27.91 $8,545 - $13,955
500 Added 1.2%
42,300 $1.15 Million
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $273,000 - $370,125
17,500 Added 72.02%
41,800 $722,000
Q2 2022

Aug 15, 2022

BUY
$13.32 - $19.98 $323,676 - $485,514
24,300 New
24,300 $425,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $631M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.